company background image
H02

Haw ParSGX:H02 Stock Report

Last Price

S$11.94

Market Cap

S$2.6b

7D

1.2%

1Y

6.4%

Updated

17 Jan, 2022

Data

Company Financials
H02 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends3/6

H02 Stock Overview

Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, ASEAN countries, other Asian countries, and internationally.

Risk Analysis

Unstable dividend track record


Price History & Performance

Summary of all time highs, changes and price drops for Haw Par
Historical stock prices
Current Share PriceS$11.94
52 Week HighS$13.80
52 Week LowS$10.96
Beta0.68
1 Month Change5.38%
3 Month Change-2.53%
1 Year Change6.42%
3 Year Change-1.16%
5 Year Change26.22%
Change since IPO462.16%

Recent News & Updates

Aug 23
Haw Par (SGX:H02) Will Pay A Dividend Of S$0.15

Haw Par (SGX:H02) Will Pay A Dividend Of S$0.15

The board of Haw Par Corporation Limited ( SGX:H02 ) has announced that it will pay a dividend of S$0.15 per share on...

Shareholder Returns

H02SG PharmaceuticalsSG Market
7D1.2%-0.7%1.5%
1Y6.4%17.0%4.4%

Return vs Industry: H02 underperformed the SG Pharmaceuticals industry which returned 17% over the past year.

Return vs Market: H02 exceeded the SG Market which returned 4.4% over the past year.

Price Volatility

Is H02's price volatile compared to industry and market?
H02 volatility
H02 Average Weekly Movement2.8%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement4.7%
10% most volatile stocks in SG Market13.5%
10% least volatile stocks in SG Market2.1%

Stable Share Price: H02 is not significantly more volatile than the rest of SG stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: H02's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1969n/aEe Lim Weehttps://www.hawpar.com

Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, ASEAN countries, other Asian countries, and internationally. The company operates through three segments: Healthcare, Investments, and Others. The Healthcare segment principally manufactures and distributes topical analgesic products.

Haw Par Fundamentals Summary

How do Haw Par's earnings and revenue compare to its market cap?
H02 fundamental statistics
Market CapS$2.64b
Earnings (TTM)S$81.77m
Revenue (TTM)S$95.99m

32.3x

P/E Ratio

27.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
H02 income statement (TTM)
RevenueS$95.99m
Cost of RevenueS$56.29m
Gross ProfitS$39.70m
Expenses-S$42.07m
EarningsS$81.77m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.37
Gross Margin41.36%
Net Profit Margin85.18%
Debt/Equity Ratio0.0%

How did H02 perform over the long term?

See historical performance and comparison

Dividends

2.5%

Current Dividend Yield

81%

Payout Ratio

Valuation

Is Haw Par undervalued compared to its fair value and its price relative to the market?

32.31x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: H02 (SGD11.94) is trading above our estimate of fair value (SGD8.56)

Significantly Below Fair Value: H02 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: H02 is poor value based on its PE Ratio (32.3x) compared to the Asian Pharmaceuticals industry average (26x).

PE vs Market: H02 is poor value based on its PE Ratio (32.3x) compared to the SG market (13.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate H02's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: H02's PB Ratio (0.8x) is in line with the SG Pharmaceuticals industry average.


Future Growth

How is Haw Par forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Haw Par has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Haw Par performed over the past 5 years?

1.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: H02 has high quality earnings.

Growing Profit Margin: H02's current net profit margins (85.2%) are lower than last year (88.6%).


Past Earnings Growth Analysis

Earnings Trend: H02's earnings have grown by 1.5% per year over the past 5 years.

Accelerating Growth: H02's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: H02 had negative earnings growth (-49.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (16.3%).


Return on Equity

High ROE: H02's Return on Equity (2.6%) is considered low.


Financial Health

How is Haw Par's financial position?


Financial Position Analysis

Short Term Liabilities: H02's short term assets (SGD612.3M) exceed its short term liabilities (SGD63.7M).

Long Term Liabilities: H02's short term assets (SGD612.3M) exceed its long term liabilities (SGD956.0K).


Debt to Equity History and Analysis

Debt Level: H02 is debt free.

Reducing Debt: H02 has no debt compared to 5 years ago when its debt to equity ratio was 2.1%.

Debt Coverage: H02 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: H02 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Haw Par current dividend yield, its reliability and sustainability?

2.51%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: H02's dividend (2.51%) is higher than the bottom 25% of dividend payers in the SG market (2%).

High Dividend: H02's dividend (2.51%) is low compared to the top 25% of dividend payers in the SG market (5.49%).


Stability and Growth of Payments

Stable Dividend: H02's dividend payments have been volatile in the past 10 years.

Growing Dividend: H02's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: At its current payout ratio (81.2%), H02's payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

10.5yrs

Average management tenure


CEO

Ee Lim Wee (60 yo)

18.25yrs

Tenure

S$1,830,000

Compensation

Mr. Ee Lim Wee serves as Deputy Chairman at UOL Group Limited. Mr. Wee has been the Chief Executive Officer and President of Haw Par Corporation Limited since October 27, 2003. Mr. Wee has been an Acting P...


CEO Compensation Analysis

Compensation vs Market: Ee Lim's total compensation ($USD1.36M) is about average for companies of similar size in the SG market ($USD1.11M).

Compensation vs Earnings: Ee Lim's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: H02's management team is seasoned and experienced (10.5 years average tenure).


Board Members

Experienced Board: H02's board of directors are considered experienced (7.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Haw Par Corporation Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Haw Par Corporation Limited
  • Ticker: H02
  • Exchange: SGX
  • Founded: 1969
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: S$2.642b
  • Shares outstanding: 221.29m
  • Website: https://www.hawpar.com

Number of Employees


Location

  • Haw Par Corporation Limited
  • No. 03-03 Haw Par Technocentre
  • 401 Commonwealth Drive
  • Singapore
  • 149598
  • Singapore

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/17 16:15
End of Day Share Price2022/01/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.